Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Artigo em Inglês | IMSEAR | ID: sea-153225

RESUMO

Background: Diabetes mellitus is a major public health problem. It is worldwide & a major risk factor for cardiovascular diseases. Glibenclamide and Glimepiride are widely used second generation sulfonylurea antidiabetic drugs. Both Glibenclamide and Glimepiride stimulate release of insulin from pancreatic acinar cells, by blocking an ATP-sensitive potassium channel. Therefore we evaluated the effect of Glimepiride and Glibenclamide on glycosylated haemoglobin in patients of type II diabetes mellitus. Aims & Objective: (1) To find out the demographic profile of type II diabetes mellitus. (2) To find out the effect of Glimepiride and Glibenclamide on glycosylated haemoglobin (HbA1c) in type II diabetes mellitus Patients. (3) To compare the effect of Glimepiride and Glibenclamide on glycosylated haemoglobin (HbA1c) among the two study groups. Material and Methods: A prospective, randomized, open, parallel group study was carried out in patients attending OPD of Medicine department MM Institute of Medical Sciences and Research (MMIMSR), Mullana, Ambala. 50 patients were randomly assigned into groups A & group B. In Group A (n=25) Glibenclamide (5-15 mg/day) & in Group B (n=25) Glimepiride (1-6 mg/day) was administered for a period of 24 weeks. Data analyzed by Student’s “t”- test. Results: It was found that prevalence of type II diabetes mellitus is more common among the male patients There was a significant reduction in glycosylated haemoglobin score (p<0.05) in both the study groups after 24 weeks but glycosylated haemoglobin level did not differ significantly (p>0.05) between the two groups. Conclusion: Glibenclamide and Glimepiride lowered glycosylated haemoglobin to a similar degree without significant difference between the two groups.

2.
Artigo em Inglês | IMSEAR | ID: sea-154005

RESUMO

Background: Diabetes mellitus is a major public health problem with many complications. The Global Burden of Diabetes Study has projected that there will be a 122% increase in the number of people with diabetes mellitus worldwide in 2025 compared to 1995. Despite the availability of new agents for the treatment of type 2 diabetes mellitus oral sulfonylureas remain a cornerstone of therapy. Glibenclamide and glimepiride are widely used sulfonylurea antidiabetic drugs. Methods: A randomized, open, parallel group study was conducted by the Department of Pharmacology in association with Department of Medicine at Maharishi Markandeshwar Institute of Medical Sciences & Research (MMIMSR), Mullana, Ambala. Total 50 patients were divided into two groups I & II. In Group I (n=25) glibenclamide (5-15 mg/day) & in Group II (n=25) glimepiride (1-6mg/day) was administered for a period of 24 weeks and data analyzed by Student’s “t”- test. Results: There was a significant improvement in the post prandial blood sugar score (p<0.05) in both the study groups (I&II) after 24 weeks but post prandial blood level did not differ significantly (p>0.05) between the two groups. Conclusions: Both the drugs glibenclamide and glimepiride were effectively reduced post prandial blood sugar in both the groups. But these sulfonylurea drugs lowered post prandial blood sugar to a similar degree without significant difference between the two groups.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA